BOLT — Bolt Biotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $23.29m
- -$50.41m
- $7.88m
- 23
- 52
- 40
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 34.8 | 22.8 | 186 | 169 | 102 |
Prepaid Expenses | |||||
Total Current Assets | 35.9 | 25.4 | 189 | 173 | 106 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11.5 | 16.4 | 30.6 | 28.5 | 24.1 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 48.4 | 46.5 | 308 | 228 | 160 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.66 | 11.3 | 21.3 | 23.1 | 20.5 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 16.8 | 46.2 | 57.6 | 56.3 | 47 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 31.7 | 0.349 | 250 | 172 | 113 |
Total Liabilities & Shareholders' Equity | 48.4 | 46.5 | 308 | 228 | 160 |
Total Common Shares Outstanding |